Literature DB >> 15827334

Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.

Kevin A Strait1, C Terry Warnick, Clyde D Ford, Bashar Dabbas, Elizabeth H Hammond, Sarah J Ilstrup.   

Abstract

Trichostatin A produces predominantly G(1) cell-cycle blockade and differentiation of the cisplatinum-sensitive A2780 ovarian cancer cell line. Given the propensity of ovarian tumors to become resistant to cisplatinum, often leading to cross-resistance to other agents, we have extended these observations by examining how the emergence of resistant phenotypes in A2780 cells affects the actions of histone deacetylase (HDAC) inhibitors. Trichostatin A exposure (100 ng/mL, 24 hours) induced ultrastructural differentiation of the "intrinsically" cisplatinum-resistant A2780-9M subline, with the reappearance of intercellular junctions and lumina containing primitive microvilli. Similar trichostatin A exposure in the acquired resistance A2780CP cells produced minimal differentiation consisting of occasional weak intercellular junctions. Independent of the differences in trichostatin A-induced differentiation, in both resistant sublines trichostatin A produced a similar reduction in cell viability, by >90%, within 5 days of treatment. Diminished viability in both A2780-9M and CP cells was associated with the absence of cell cycle arrest in G1, resulting in predominant G2-checkpoint arrest accompanied by a 10- to 20-fold increase in Annexin V binding and the reemergence of apoptosis. Similar cell cycle arrests and apoptosis were also observed using other HDAC inhibitors and in other resistant ovarian cancer cell lines (OVCAR-3 and SK-OV-3). Trichostatin A-induced apoptosis in resistant cells is in sharp contrast to its effects on the parental cisplatinum-sensitive A2780 and normal MRC-5 fibroblast cell lines (predominant cycle arrest in G1 with no detectable apoptosis). Western immunoblot analysis indicated trichostatin A triggers apoptosis in resistant ovarian cancer cells via p53-independent activation of the intrinsic "mitochondrial" pathway, commensurate with induction of the Bcl-2-related protein Bad. These results suggest cisplatinum resistance alters the effects of HDAC inhibition through a shift in cell cycle arrest from the G1 to the G2 checkpoint and reactivation of the intrinsic mitochondrial apoptotic cascade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827334     DOI: 10.1158/1535-7163.MCT-04-0107

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  17 in total

1.  Evaluation of royal jelly as an alternative to fetal bovine serum in cell culture using cell proliferation assays and live cell imaging.

Authors:  Marahaini Musa; Nurul Fatihah Mohamad Nasir; Kannan Ponnuraj Thirumulu
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

2.  The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.

Authors:  Andrew J Wilson; Edward Holson; Florence Wagner; Yan-Ling Zhang; Daniel M Fass; Stephen J Haggarty; Srividya Bhaskara; Scott W Hiebert; Stuart L Schreiber; Dineo Khabele
Journal:  Cancer Biol Ther       Date:  2011-09-15       Impact factor: 4.742

Review 3.  Latest research and treatment of advanced-stage epithelial ovarian cancer.

Authors:  Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

4.  Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.

Authors:  Himavanth R Gatla; Yue Zou; Mohammad M Uddin; Bipradeb Singha; Pengli Bu; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2017-02-06       Impact factor: 5.157

Review 5.  The emerging role of lysine acetylation of non-nuclear proteins.

Authors:  Pierre Close; Catherine Creppe; Magali Gillard; Aurélie Ladang; Jean-Paul Chapelle; Laurent Nguyen; Alain Chariot
Journal:  Cell Mol Life Sci       Date:  2010-01-16       Impact factor: 9.261

6.  BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.

Authors:  Katherine V Clark-Knowles; Anna M O'Brien; Johanne I Weberpals
Journal:  J Oncol       Date:  2010-02-22       Impact factor: 4.375

7.  The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

Authors:  David M Woods; Karrune Woan; Fengdong Cheng; Hongwei Wang; Patricio Perez-Villarroel; Calvin Lee; Maritza Lienlaf; Peter Atadja; Edward Seto; Jeffrey Weber; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Melanoma Res       Date:  2013-10       Impact factor: 3.599

8.  A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

Authors:  Ya-Ting Yang; Curt Balch; Samuel K Kulp; Michael R Mand; Kenneth P Nephew; Ching-Shih Chen
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

Review 9.  Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.

Authors:  Kristy R Stengel; Scott W Hiebert
Journal:  Antioxid Redox Signal       Date:  2014-06-26       Impact factor: 8.401

10.  Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.

Authors:  Wilko Weichert; Carsten Denkert; Aurelia Noske; Silvia Darb-Esfahani; Manfred Dietel; Steve E Kalloger; David G Huntsman; Martin Köbel
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.